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Abstract
DJ-1 is an oxidation sensitive protein encoded by the PARK7 gene. Mutations in PARK7 are a rare cause of familial recessive
Parkinson’s disease (PD), but growing evidence suggests involvement of DJ-1 in idiopathic PD. The key clinical features of PD,
rigidity and bradykinesia, result from neurotransmitter imbalance, particularly the catecholamines dopamine (DA) and nor-
adrenaline. We report in human brain and human SH-SY5Y neuroblastoma cell lines that DJ-1 predominantly forms high mo-
lecular weight (HMW) complexes that included RNA metabolism proteins hnRNPA1 and PABP1 and the glycolysis enzyme
GAPDH. In cell culture models the oxidation status of DJ-1 determined the specific complex composition. RNA sequencing in-
dicated that oxidative changes to DJ-1 were concomitant with changes in mRNA transcripts mainly involved in catechol-
amine metabolism. Importantly, loss of DJ-1 function upon knock down (KD) or expression of the PD associated form L166P
resulted in the absence of HMW DJ-1 complexes. In the KD model, the absence of DJ-1 complexes was accompanied by im-
pairment in catecholamine homeostasis, with significant increases in intracellular DA and noraderenaline levels. These
changes in catecholamines could be rescued by re-expression of DJ-1. This catecholamine imbalance may contribute to the
particular vulnerability of dopaminergic and noradrenergic neurons to neurodegeneration in PARK7-related PD. Notably,
Received: May 24, 2017. Revised: July 18, 2017. Accepted: July 19, 2017
VC The Author 2017. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
4028
Human Molecular Genetics, 2017, Vol. 26, No. 20 4028–4041
doi: 10.1093/hmg/ddx294
Advance Access Publication Date: 25 July 2017
Original Article
oxidised DJ-1 was significantly decreased in idiopathic PD brain, suggesting altered complex function may also play a role in
the more common sporadic form of the disease.
Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder charac-
terized by typical motor symptoms including bradykinesia, ri-
gidity and resting tremor in later stages of the disease when up
to 80% of dopaminergic neurons in the brain are lost (1,2). In ad-
dition to the dopaminergic system other neurotransmitters are
affected, in particular the noradrenergic system (3–5).
The PARK7 gene encodes the protein DJ-1 and mutations in
this gene are a rare cause of autosomal-recessive early-onset
parkinsonism. These mutations generally result in a loss-of-
function of the protein (exon 1-5 deletion, L166P, L172Q).
Increasing evidence suggests that there are different subcellular
pools of DJ-1, with the largest proportion of DJ-1 being localised
in the cytosol and minor amounts resident in mitochondria and
nuclei of cultured cells and brain (6–11).
DJ-1 has been suggested to be involved in many cellular
processes, including transcriptional and translational regula-
tion, protein quality control and mitochondrial function
(6,7,10,12–18). DJ-1 has also been linked to neurotransmitter ho-
meostasis. It has been reported to affect dopamine (DA) re-
uptake in HEK-293 T cells (19) and synthesis in SH-SY5Y cells
(18). Dopaminergic neurons have been reported to be protected
against DA toxicity by DJ-1 via control of the vesicular seques-
tration of DA and upregulation of VMAT2 (20). Conversely, DJ-1
deficiency impairs the expression of neurotransmitter receptors
and neurotransmission (21,22).
There is common agreement that DJ-1 acts as a sensor for
oxidative stress and that its reactive cysteine residues C46, C53,
and C106 are involved in the protein’s regulation. It has been
suggested that C106 is the most sensitive residue to oxidation
and might therefore act as a molecular switch for the activity of
the protein (7,23). Since DJ-1 has clearly been linked to oxidative
stress, which represents one of the key features of PD on the
molecular level (24), understanding the protein’s role in cellular
stress response might provide new insights into the processes
underlying sporadic forms of the disease. Moreover, under-
standing the effects of loss-of-function of DJ-1 might identify
new therapeutic strategies and reveal novel mechanisms
critical for disease pathogenesis and/or early events resulting in
neuronal death.
Several studies have shown that wild type DJ-1 is part of
high molecular weight (HMW) complexes in human brain as
well as in cultured cells. Different sizes have been observed for
the described complexes, ranging from 70 kDa up to 2 MDa with
conflicting protein constituents (25–28). Some of the specific
functions of DJ-1-containing HMW protein complexes include
protein degradation via the ubiquitin-proteasome-system (28),
prevention of alpha-synuclein accumulation (15) and RNA regu-
lation (29,30). We hypothesised that DJ-1 binds various proteins
to form HMW complexes that can regulate the function/local-
isation of these proteins within cells and furthermore that the
oxidation status of DJ-1 might orchestrate the composition of
these complexes.
Here, we show in human neuroblastoma cells and brain that
DJ-1 forms HMW complexes, and that DJ-1 loss of function re-
sulted in transcriptional dysregulation of genes involved in neu-
rotransmitter synthesis, transport, storage and release. Loss of
DJ-1 complexes in vitro increased intracellular catecholamine
levels in human neuroblastoma cells and may provide an in-
sight for the role of DJ-1 in PD pathogenesis.
Results
Levels of dimeric and oxidized monomeric DJ-1 are
decreased in PD brain
Several groups have reported altered levels of total or oxidised
forms of DJ-1 in human post mortem tissue of PD patients, al-
though results are not consistent (31–33). We performed SDS
PAGE and western blotting analysis on post mortem tissue from
cortex of age-matched controls (n¼ 10) and PD patients (n¼ 10)
using two different antibodies to differentiate between mono-
meric, dimeric and DJ-1 oxidised at cysteine residue 106 (C106;
(34)) (Fig. 1A). Levels of monomeric DJ-1 varied between individ-
uals, but no significant difference was observed between con-
trols and PD patients. However, levels of oxidised DJ-1 (oxDJ-1)
were significantly decreased in PD brains by 25.5% (P< 0.01) (Fig.
Figure 1. Levels of dimeric and oxidised DJ-1 are altered in human PD brain. (A) SDS PAGE and western blot analysis of human post mortem tissue lysates from 10 con-
trol individuals versus 10 PD patients. Membranes were probed for total DJ-1 (Enzo mouse monoclonal) to detect monomeric and dimeric forms of the protein. An anti-
body that detects oxidized DJ-1 at residue C106 (oxDJ-1) was also used. b-actin was used as a loading control. (B) Quantification of the western blots shown in
(A). Statistical significance was calculated by one-way ANOVA with post hoc Tukey HSD test. *P<0.05; ***P<0.01 vs. control.
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1B). Similarly, SDS-resistant dimeric DJ-1 was decreased by
44.5% in PD brains (P< 0.05). The oxDJ-1 antibody did not detect
dimeric DJ-1, suggesting that DJ-1 dimers are not oxidised.
However, it cannot be discounted that the epitope is concealed
in the dimeric form or that the levels of dimeric compared to
monomeric were below the detection limit of the antibody. In
summary, alterations in the levels of oxidised and dimeric DJ-1
appeared to be associated with PD.
Complex bound DJ-1 is the predominant form of the pro-
tein in human brain
We hypothesised that participation of DJ-1 in the formation of
variable complexes could account for its numerous reported
functions. To detect soluble DJ-1 containing HMW complexes in
human post mortem tissue (putamen) we performed blue na-
tive (BN) PAGE. Western blotting identified several DJ-1 com-
plexes (Fig. 2A, left panel) including dimer (Fig. 2A, arrow). To
confirm that these HMW species contained DJ-1 we performed
combined two-dimensional BN and SDS PAGE. The HMW com-
plexes all yielded monomeric DJ-1 at the expected molecular
weight (Fig. 2A, right panel). A similar pattern of complexes was
detected in the cortex (Fig. 2B), amygdala and substantia nigra
(Supplementary Material, Fig. S1). The total amount of DJ-1
complexes in the putamen was significantly increased in PD
brains (Supplementary Material, Fig. S1A; P< 0.01), while there
was no difference in the amygdala or substantia nigra. It should
be noted that the same pattern of complexes was seen indepen-
dently of post mortem delay (range: 3–89.2 h) suggesting that
this pattern was not due to degradation following extraction.
Furthermore, these complexes appear very stable as complexes
extracted from cells or human brain could be kept in sucrose
buffer at 4 C for up to two weeks and still yield the same west-
ern blot pattern (data not shown).
Due to the different cell-types in brain, the observed pattern
of DJ-1 complexes in human brain could reflect cell-type specific
complexes. Alternatively, the different complexes might reflect
the oxidation state of DJ-1 at C106. Therefore, we probed the
DJ-1 complexes in control and PD cortex with oxDJ-1 antibody
and observed that all HMW species were positive for oxidised
DJ-1 (Fig. 2B). The two PD cortex samples suggest that there are
less DJ-1 positive HMW complexes than in control brains.
Complex bound DJ-1 is the predominant species also in
SH-SY5Y cells
To investigate if DJ-1 forms similar HMW complexes in cultured
cells, we analysed DJ-1 complex formation in the human neuro-
blastoma SH-SY5Y cell line by BN PAGE. Western blotting using
antibody that labels total DJ-1 identified one DJ-1 complex with
a similar molecular weight to the largest complex in the human
brain (Fig. 3A). The HMW complex was almost absent in the
constitutive DJ-1 knock down (KD) cell lines KD1 and KD2 (Fig.
3B left panel), when compared to the parental SH-SY5Y cell line
(SH) or SH-SY5Y expressing scrambled control shRNA (SC1).
Analysis of total DJ-1 protein levels by SDS-PAGE and western
blotting indicated that< 20% endogenous DJ-1 is expressed in
KD cells compared to the SH or SC1 cell lines (Supplementary
Material, Fig. S2A and B). Re-introduction of wild type (WT) DJ-1
rescued complex formation, while over expression of WT DJ-1
in normal SH-SY5Y cells resulted in increased complex levels
(Fig. 3B middle and right panel).
DJ-1 is predominantly localised in the cytosol but there is
also a mitochondrial DJ-1 pool (7,8,13). Subcellular fractionation
of SH-SYSY cells followed by BN-PAGE showed that the HMW
DJ-1 complex was present in the cytosolic fraction
(Supplementary Material, Fig. 2C). Although BN-PAGE did not
detect DJ-1 HMW complex in mitochondria, SDS-PAGE followed
by Western blotting indicated that wild-type DJ-1 can be de-
tected in both cytosolic and mitochondrial fractions, as previ-
ously described (7,8).
In human brain material, complex bound DJ-1 was the pre-
dominant form of the protein (Fig. 2). Therefore, we investigated
the proportions of monomeric, dimeric and complex bound DJ-1
in SH-SY5Y cells by BN PAGE using gradient gels. The increased
resolution indicated that there are at least two HMW complexes
Figure 2. DJ-1 HMW complexes are the predominant species in human brain and show evidence of oxidation. (A) Left: Soluble complexes from putamen of three
healthy individuals were examined using 8-16% gradient BisTris gels and subsequent western blot analysis for total DJ-1. No monomeric DJ-1 was detectable in puta-
men in native lysates. However, based on its molecular weight a band perhaps representing DJ-1 homodimer was detected (indicated by arrow). Representative west-
ern blot is shown (n¼3). Right: The soluble complexes from human putamen were analysed by two dimensional BN/SDS PAGE and western blotting for total DJ-1,
which was detectable in all four complexes, illustrating that the DJ-1 signal is specific. Representative western blot is shown (n¼2). (B) Soluble complexes from cortex
of two healthy individuals and two PD patients were separated on 7.5% fixed percentage BisTris gels and subsequently probed for oxidized DJ-1 (ox DJ-1) and total DJ-1.
Representative western blot is shown (n¼2). Protein loading of brain samples used for BN-PAGE was assessed by measuring an aliquot of each sample for b-actin by
SDS-PAGE (panel underneath BN PAGE).
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Figure 3. Oxidation of DJ-1 affects complex formation. (A) Soluble complexes from SH-SY5Y cells and control human putamen brain samples were separated by BN
PAGE using 7.5% BisTris gels and western blot analysis for DJ-1 was performed. (B) Left: Soluble protein complexes were extracted from SH-SY5Y, scrambled control
(SC1), DJ-1 knock down (KD1 and KD2) cells and separated by BN PAGE on 7.5% BisTris gels. Middle: Transfection of WT DJ-1 into the KD background rescued complex
formation after 72 h. Right: Over expression of WT DJ-1 in SH-SY5Y cells slightly increased the amount of complex after 72 h compared to untransfected SH-SY5Y cells.
Representative western blots are shown (n>3). (C) To compare total amounts of monomeric, dimeric and complex bound DJ-1, soluble protein complexes were ex-
tracted from SH-SY5Y cells, KD1 and KD1 cells transfected with WT DJ-1 or C106DD DJ-1 72 h after transfection. Complexes were separated on 8-16% gradient BisTris
gels and western blot analysis was performed probing for DJ-1. Representative western blot results are shown (n>3). Protein loading of samples used for BN-PAGE was
assessed by measuring an aliquot of each sample for DJ-1 and b-actin level by SDS-PAGE (panels underneath BN PAGE). (D) Left: SDS PAGE and western blot analysis
was performed with KD1 cells transiently transfected with wild type DJ-1 (WT), the oxidation deficient mutant DJ-1 form C106A (A) or the oxidation mimicking DJ-1
form C106DD (DD). Membranes were probed for oxidised DJ-1 (oxDJ-1) and total DJ-1. Right: SDS PAGE and western blot analysis was performed with KD1 cells, untrans-
fected or transiently transfected with WT or DD DJ-1 Cells were either untreated or stress treated with 1 mM H2O2 for 1 h to induce oxidation of DJ-1. Membranes were
probed for oxidised DJ-1 (oxDJ-1) and b-actin. (E) Soluble protein complexes were extracted from SH-SY5Y cells, KD1, KD1 expressing WT or C106DD DJ-1and separated
by BN PAGE on 8-16% BisTris gels. Cells were either stress treated with 1 mM BSO for 24 h and subsequently 1 mM H2O2 for 30 min or left untreated. Left: short exposure
probing for total DJ-1. Middle: longer exposure of the same membrane. Right: Membrane probed for oxidised DJ-1 (ox DJ-1). The dotted line denotes the molecular
weight of WT DJ-1 complex under basal conditions and indicates that treatment induced oxidation of DJ-1 results in a slightly higher molecular weight of the complex
(F) Soluble protein complexes were extracted from SH-SY5Y cells either stress treated (1 mM BSO for 24 h and subsequently 1 mM H2O2 for 30 min) or left untreated.
Samples were separated by BN PAGE on 8-16% BisTris gels and western blot analysis for total and oxidised DJ-1 was performed. Left: longer exposure probing for total
DJ-1. Middle: shorter exposure of the same membrane. Right: Membrane probed for oxidised DJ-1. The arrow indicates another complex detected by total DJ-1 antibody
in oxidation treated SH-SY5Y cells with the same molecular weight as C106DD DJ-1 complex.
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containing DJ-1 in SH-SY5Y cells and WT cells within a size
range of 242 and 480 kDa (Fig. 3C). A minor signal at around
50 kDa which could represent the DJ-1 homodimer was only
detectable upon extended exposure of the western blots
(Supplementary Material, Fig. S3A).
Oxidation state of DJ-1 affects complex formation
We next investigated the impact of C106 oxidation on complex
formation in SH-SY5Y cells. Mutation of cysteine 106 to alanine
(C106A) prevents oxidation of this residue, while mutation of
the same residue to an aspartic acid doublet (C106DD) is
thought to mimic sulfinic acid oxidative modification (-SO2H)
and has been shown to be critical for DJ-1 function (12). WT or
C106DD plasmids were transiently transfected into the DJ-1 KD
cell line KD1 to create cells predominantly expressing the DJ-1
form of interest. Note that the siRNA in KD1 targets the 3’UTR of
endogenous DJ-1 mRNA and thus plasmid encoded WT or
C106DD DJ-1 mRNA transcripts were unaffected. BN PAGE
revealed that transfection of KD1 cells with C106DD resulted in
the formation of at least three different complexes of lower
molecular weight that were closer to 242 kDa (Fig. 3C). The
oxidation-mimic C106DD was readily detected by the oxDJ-1 an-
tibody by SDS-PAGE, while WT-DJ-1 was detected only after oxi-
dative stress treatment (1 mM BSO for 24 h and 1 mM H2O2 for
1 h; Fig. 3D), indicating that DJ-1 C106DD protein adequately
mimics endogenous DJ-1 oxidized at C106.
Similar results were observed in KD1 cells with stable ex-
pression of WT or C106DD DJ-1 cells. WT and DD stable cell lines
expressed 4.1 and 5.6-fold more DJ-1 than parental SH-SY5Y
cells, respectively (Supplementary Material, Fig. S3D). The oxDJ-
1 antibody also detected C106DD in HMW DJ-1 complexes sepa-
rated by BN-PAGE (Fig. 3E), whereas WT DJ-1 was detected only
following oxidative stress treatment (Fig. 3E, right panel). The
dotted line in Figure 3E denotes the molecular weight of com-
plexes containing WT DJ-1 under basal conditions and indicates
that treatment induced oxidation of DJ-1 results in a higher mo-
lecular weight of the complex. The lower molecular weight
forms of these complexes seen in C106DD cells were not de-
tected following induction of oxidative stress in cells expressing
WT DJ-1. Probing for total DJ-1 confirmed that WT DJ-1 com-
plexes slightly shifted up following oxidative stress (Fig. 3E,
middle panel). Treatment of parental SH-SY5Y cells with the
same oxidising conditions also resulted in a modest increase in
HMW DJ-1 complex size (Fig. 3F). The arrow in Figure 3F indi-
cates another complex in treated SH-SY5Y cells with the same
molecular weight as observed upon expression of DJ-1 C106DD.
These results demonstrate that oxidation of DJ-1 affects the
size and probably the composition of DJ-1 HMW complexes.
However, the HMW complexes formed by the oxidation-mimic
C106DD DJ-1 migrate differently compared to oxidised endoge-
nous DJ-1 HMW complexes. It cannot be excluded that the extra
aspartic acid residue may affect the charge of the protein and
hence it’s migration through the gel.
DJ-1 complexes are absent upon expression of the PD
associated DJ-1 mutant L166P
The PD-associated mutation DJ-1 L166P has been shown to be
less stable resulting in its premature proteasomal degradation
(35,36). In KD1 cells transiently transfected with DJ-1 L166P
HMW protein complexes were absent (Fig. 4A). To ensure that
the L166P DJ-1 protein was expressed following transfection, we
performed SDS PAGE and western blotting. Protein levels were
substantially reduced (Fig. 4B). To ensure efficient transfection,
mRNA levels were analysed by quantitative real-time PCR
(qPCR). qPCR results confirmed substantially increased DJ-1
mRNA levels (SH-SY5Y, 10065%; KD1, 96 23%; KD1þWT DJ-1,
1738646 12%; KD1þ L166P DJ-1, 656826 15%). Therefore, in our
experimental model, DJ-1 L166P is unstable and results in pro-
tein levels similar to KD1 cells and thus were unable to detect
HMW DJ-1 complexes in these cells.
Composition of DJ-1 HMW complexes
Our experiments suggested altered complex composition of DJ-
1 complexes in an oxidation dependent manner (Fig. 3).
Immunoprecipitation of DJ-1 WT HMW complexes from SH-
SY5Y cells was performed to analyse the composition of the
complexes by label-free quantitative liquid chromatography
tandem mass spectrometry (LC-MS/MS; (37)). A band of the cor-
rect molecular weight was detected following immunoprecipi-
tation with DJ-1 antibody and was barely detectable or absent
when the immunoprecipitation was performed in either KD1
cells or without DJ-1 antibody, respectively (Supplementary
Material, Fig. S4A). Identified proteins are listed in
Supplementary Material, Table S1. DJ-1 was present in all four
runs and the second most common protein. The total number
of DJ-1 peptides was 62 with 94% coverage of the protein. The
identified proteins included Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH), Hsp60, SOD1 and three isoforms of hetero-
geneous ribonucleoproteins (A1, C1C2 and A2B1), the putative
elongation factor 1 alpha like 3 (EF1A3) and the splicing regula-
tory glutamine lysine rich protein 1 (SREK1). Note that trypsin is
from the mass spectrometry protocol and yeast enolase is used
as a control.
BN-PAGE of SH-SY5Y lysates followed by western blotting
for hnRNPA1 indicated that it was present in a HMW complex
with a similar migration to DJ-1 (Supplementary Material, Fig.
S5A). Furthermore immunoprecipitation of hnRNPA1 from SH-
SY5Y cells co-immunoprecipitated DJ-1 (Supplementary
Figure 4. DJ-1 complexes are not detected upon expression of the PD associated
DJ-1 mutant L166P. (A) Soluble protein complexes were extracted from KD1 cells
transfected with WT DJ-1 or L166P DJ-1 72 h after transfection. Complexes were
separated on 8–16% gradient BisTris gels and western blot analysis was per-
formed probing for DJ-1. In cells expressing the PD associated mutation DJ-1
L166P the complex was absent. Representative western blot results are shown
(n¼2). (B) Analysis of total DJ-1 levels in the same samples by SDS PAGE and
western blotting revealed that introduction of WT-DJ-1 in to KD1 cells signifi-
cantly increased total DJ-1 levels. However total DJ-1 levels in KD1 cells express-
ing DJ-1 L166P were almost as low as in KD1 cells alone. b-actin was used as
loading control. Representative western blot is shown.
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Material, Fig. S5B). Two-dimensional BN and SDS-PAGE also in-
dicated that hnRNPA1 and GAPDH co-migrated with DJ-1
(Supplementary Material, Fig. S5C and F).
To elucidate the effect of oxidative stress we compared DJ-
1 HMW complexes obtained from KD1 cells expressing DJ-1
C106A and DJ-1 C106DD by the same LC-MS/MS technique. We
chose C106A rather than the parental cell line or KD1 cells ex-
pressing WT-DJ-1, since C106A is unable to be oxidised at this
residue. We did not analyse endogenous complexes treated
with oxidising conditions (Fig. 3C and F) as it is likely that sev-
eral other residues, in addition to C106, are oxidised under
these conditions. Equal expression levels of C106A and
C106DD DJ-1 in the cells used for this experiment were con-
firmed by SDS PAGE and western blot (Supplementary
Material, Fig. S4B). The differences identified between the two
samples are listed in Supplementary Material, Table S2 to-
gether with their mean amount in fmol and the respective
fold change between the samples for each protein (C106DD/
C106A). The greatest change was a five-fold reduction of het-
erogeneous ribonucleoprotein A1 like 2 (hnRNPA1L2; 19.9%) in
the complex containing DJ-1 C106DD. hnRNPA1L2 has 97%
protein homology to hnRNPA1, which was also found to be de-
creased (58%). Several additional proteins associated with
RNA metabolism, such as other hnRNPs family members
(A2B1, A3, A0, C1C2Q, D0, F, H, K, L, M, R, U) and
polyadenylate-binding protein 1 (PABP1; decreased by 54%)
were found to be altered in C106DD cells. GAPDH (also found
in initial mass spectrometry of endogenous DJ-1 HMW com-
plexes) was also slightly decreased, as was hsc70 (also known
as hsp7c), a protein involved in chaperone-mediated autoph-
agy of a-synuclein, and reported to be decreased in sporadic
PD (38).
BN-PAGE analysis for PABP1 indicated that this protein was
present in WT DJ-1 HMW complexes. Furthermore, a PABP1 sig-
nal was detected in cells expressing C106DD DJ-1 at the ex-
pected lower molecular weight (Supplementary Material, Fig.
S5D). Two-dimensional BN and SDS-PAGE indicated that both
hnRNPA1 and PABP1 co-migrated with DJ-1 in KD1 cells ex-
pressing WT-DJ-1 (Supplementary Material, Fig. S5C and E). The
hnRNP1 spot was decreased in cells expressing C106DD
(Supplementary Material, Fig. S5C). Two PABP1 spots of the cor-
rect molecular weight were detected that co-migrated with DJ-1
(Supplementary Material, Fig. S5E). In cells expressing C106DD
DJ-1 one of these spots was not detected. GAPDH and hsc70 also
co-migrated with DJ-1 (Supplementary Material, Fig. S5F). In
summary, DJ-1 complexes contained largely RNA binding pro-
teins and the composition appears to be altered by the oxida-
tion status of DJ-1.
Transcriptome alterations are consistent with altered
DJ-1 complex composition
We next wanted to understand the effect of oxidation of DJ-1 on
complex bound RNA binding proteins. Analysis of small RNAs
(miRNA; piRNA; rRNA; snoRNA); small nuclear RNA (snRNA))
and larger RNAs (mainly mRNA) by RNA sequencing revealed
differences in miRNA and mRNA species only. All other small
RNA species were largely unaffected. The mapping statistic for
the RNA sequencing is shown in Supplementary Material, Table
S3. We correlated changes in miRNAs with the respective
changes in mRNA in order to extract inversely correlated
miRNA-mRNA pairs, to increase the overall reliability of the
data. The top hits of inversely correlated miRNA-mRNA pairs
are shown in Table 1. These included several neurotransmitter
associated targets such as Vesicular monoamine transporter 1
(SLC18A1/VMAT1), Solute Carrier Family 1 Neuronal/Epithelial
High Affinity Glutamate Transporter (SLC1A1), and Dopamine
receptor 2 (DRD2). Notably one of the top hits was apoptosis sig-
naling kinase 1 (MAP3K5/ASK1), which has previously been
shown to be partially activated in cells expressing C106DD DJ-1
and to be cytoprotective (12). Assessment of gene ontology (GO)
terms for both up regulated and down regulated mRNA species
is shown in Supplementary Material, Figure S8. Biological regu-
lation, metabolic process, membrane, nucleus, vesicle, and pro-
tein binding featured strongly for both up and down regulated
mRNA.
Differentially regulated mRNAs (without correlation to
miRNAs) were related to synthesis, transport, release & metabo-
lism of neurotransmitters, especially catecholamines and gluta-
mate. These included dopa decarboxylase (DDC), VMAT1 and
dopamine b hydroxylase (DBH) (Table 2). Confirming the RNA
sequencing data, qPCR of VMAT1, DBH and ASK1 mRNA showed
significantly increased levels in cells expressing DJ-1 C106DD
when compared to expression of DJ-1 WT (Fig. 5A; VMAT1: 3-
fold, P< 0.01; DBH: 3.2-fold, P< 0.05; ASK1: 1.6-fold, P< 0.05). In
DJ-1 KD cells (KD1), VMAT1 mRNA levels were significantly de-
creased by 3.2-fold (P< 0.001), whereas DBH mRNA levels re-
mained unchanged and ASK1 mRNA levels increased 1.8-fold,
P< 0.05 (Fig. 5B). Oxidative stress treatment of parental SH-
SY5Y cells significantly increased both VMAT1 (1.3-fold,
P< 0.05) and DBH mRNA levels (1.6-fold, P< 0.05; Fig. 5C),
whereas KD1 cells lacking DJ-1 were unable to increase either
transcript (Fig. 5D). In summary, RNA sequencing and qPCR sug-
gest that alterations of DJ-1 HMW complex composition are con-
comitant with changes in the transcription of several
neurotransmitter-related targets.
KD of DJ-1 increased catecholamine levels
Several of the upregulated transcripts are directly involved in
the synthesis of DA (DDC), transport of DA into vesicles
(VMAT1) and its metabolism to noradrenaline (DBH; Fig. 6A). We
thus measured the levels of intracellular DA (Fig. 6B) and nor-
adrenaline (NOR; Fig. 6C) in our cell models by ELISA. KD of DJ-1
in KD1 cells increased DA levels 2-fold compared to normal SH-
SY5Y cells (KD1, 11.8360.65 pg/mg protein; SH, 5.996 0.49 pg/
mg protein; P< 0.01). The constitutive expression of WT or
C106DD DJ-1 in KD1 cells rescued the KD phenotype by signifi-
cantly decreasing DA levels, compared to KD1 (WT,
6.5660.77 pg/mg protein; DD, 6.8560.37 pg/mg protein). Similar
results were obtained for NOR. When compared to SH-SY5Y
cells, intracellular NOR levels in KD1 cells were increased 4.8-
fold (KD1, 342.296 14.74 pg/mg protein; SH, 70.8262.37 pg/mg
protein, P< 0.01), while re-introduction of WT or C106DD DJ-1
reduced NOR levels compared to KD1 cells (WT, 78.816 9.85 pg/
mg protein and DD, 126.3567.88 pg/mg protein). These results
demonstrate that re-introduction of DJ-1, irrespective of
whether WT or C106DD, is sufficient to rescue this phenotype
and that cellular levels of DJ-1 are critical to balance catechol-
amine levels. Adrenaline (AD) levels were increased in KD1, and
were not reversed by expression of WT or C106DD DJ-1
(Supplementary Material, Fig. S6).
We further analysed the effect of oxidative stress treatment
(OX; L-BSOþH2O2) on catecholamine levels (Fig. 7). DA levels in
WT cells increased 1.8-fold following treatment (WT,
6.5660.77 pg/mg protein vs. WTþOX, 11.896 0.33 pg/mg, Fig.
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7A; P< 0.01), while in DD cells DA levels did not increase signifi-
cantly following treatment (Fig. 7A).
NOR levels in WT cells were also significantly increased fol-
lowing treatment (WT, 78.8169.86 pg/mg protein; WTþOX,
116.546 9.58 pg/mg, P< 0.05). NOR levels in DD cells were
similar to treated WT cells (Fig. 7B) and did not change af-
ter treatment (DD, 126.356 7.88 pg/mg protein; DDþOX,
110.826 13.63 pg/mg protein). Oxidative stress treatment of
parental SH-SY5Y cells also increased DA levels by 3.81-fold
(SH-SY5Y; 5.9960.49 pg/mg protein vs SH-SY5YþOX;
22.8261.55 pg/mg protein), but not NOR or AD (Supplementary
Material, Fig. S7).
Discussion
PARK7-related PD is autosomal recessive caused by DJ-1 loss-of-
function. We report that DJ-1 forms HMW complexes in human
brain and SH-SY5Y cells. Analysis of these complexes in SH-
SY5Y cells indicated that they contain RNA-related proteins
such as PABP1 and hnRNPA1. KD of DJ-1 meant these complexes
were not formed, and was accompanied by alterations of mRNA
transcripts important for the catecholaminergic system and
increased intracellular levels of DA and NOR. DJ-1 HMW com-
plexes could not be detected in cells expressing the PD-
associated DJ-1 mutation L166P.
DJ-1 structure in sporadic and PARK7-related PD
Decreased levels of DJ-1 mRNA, monomeric and oxidized forms
of DJ-1 have been observed in PD patients in several previous
studies (31–33). In human PD brain we found total protein levels
of monomeric DJ-1 were unaffected in all regions tested. Levels
of oxidized monomeric and unoxidized dimeric DJ-1 however
were significantly decreased in sporadic PD patients compared
Table 1. Top up and down regulated mRNA targets in DD cells when compared to WT cells that showed inverse correlation with their respec-
tive miRNAs
Gene Description Pathway log2 fold change P-value
Down regulated
SGK1 Serum and glucocorticoid-regulated kinase 1 HD signaling 2.73 1.47E-68
TGM2 Tissue transglutaminase 2 HD signaling 2.28 2.66E-75
ITGA5 Integrin alpha-5 Apoptosis 2.16 3.43E-09
CPLX2 Complexin-2 HD signaling 1.94 6.17E-36
SYK Spleen tyrosine kinase Inflammation 1.87 8.50E-36
PRKCA Protein kinase C alpha type Apoptosis 1.76 5.36E-157
GRIP1 Glutamate receptor-interacting protein 1 Glutamate receptor signaling 1.71 3.12E-48
GRIN1 Glutamate receptor ionotropic, NMDA 1 Dopamine/cAMP signaling; Glutamate recep-
tor signaling
1.56 4.00E-03
CAPN6 Calpain-6 Apoptosis 1.54 4.05E-05
KCNJ3 G protein-activated inward rectifier potas-
sium channel 1
Dopamine/cAMP signaling 1.44 1.83E-02
GRM2 Metabotropic glutamate receptor 2 Glutamate receptor signaling 1.31 3.19E-02
CACNA1C Voltage-dependent L-type calcium channel
subunit alpha-1C
Dopamine/cAMP signaling 1.01 4.08E-04
GRM7 Metabotropic glutamate receptor 7 Glutamate receptor signaling 0.89 1.18E-11
Up regulated
SLC18A1/ VMAT1 Solute carrier 18A1/vesicular monoamine
transporter 1
Dopamine receptor signalling 1.66 1.75E-229
MAP3K5/ ASK1 Mitogen-activated protein kinase kinase ki-
nase 5/Apoptosis signal-regulating kinase
1
Apoptosis 1.16 4.64E-20
CYGB Cytoglobin Superoxide radical degradation 1.04 1.29E-29
MYCN N-myc proto-oncogene protein ERK/MAPK signaling 0.94 7.32E-10
HSPA1A Heat shock 70 kDa protein 1A HD signaling 0.76 7.59E-08
CCND1 Cyclin-D1 cell cycle control (PI3/Akt) 0.63 5.77E-42
MAPK11 Mitogen-activated protein kinase 11 PD signaling 0.63 9.45E-11
SLC1A1 Solute carrier 1A1/Excitatory amino acid
transporter 3
Glutamate receptor signaling 0.61 1.78E-05
THEM4 Acyl-coenzyme A thioesterase Cell cycle control (PI3/Akt) 0.55 1.92E-06
BMPR1B Bone morphogenetic protein receptor type-1B PTEN signaling 0.48 3.92E-09
Hsc70 Heat shock 70 kDa protein 8/Heat shock cog-
nate 71 kDa protein
HD signaling 0.46 3.27E-16
DRD2 Dopamine receptor D2 Dopamine receptor signalling; Dopamine/
cAMP signaling
0.45 7.31E-04
KCNJ8 ATP-sensitive inward rectifier potassium
channel 8
Dopamine/cAMP signaling 0.44 7.68E-07
PIK3R1 Phosphatidylinositol 3-kinase regulatory sub-
unit alpha
HD signaling 0.43 1.26E-07
RPS24 40S ribosomal protein S24 PD signaling 0.38 6.27E-03
IFT57 Intraflagellar transport protein 57 homolog HD signaling 0.38 6.99E-07
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to controls. These data suggest that the decrease in oxidized
monomeric and unoxidised dimeric DJ-1 might be of relevance
to PD pathophysiology.
DJ-1 has been observed to dimerise and form oligomers
with other DJ-1 molecules, but the functional consequence
of this phenomenon has been speculative (11,35,36,39,40).
We show that in both control brain and SH-SY5Y cells,
HMW DJ-1 complexes (240–480 kDa) are the predomi-
nant form of the protein, with some dimer present. HMW DJ-
1 complex formation appears to be dependent on DJ-1
Table 2. Top up and down regulated mRNA targets in DD cells when compared to WT cells irrespective of miRNAs
Gene Description log2 fold change P-value
Down regulated
MOXD1 Monooxygenase, DBH-like 1 4.47 4.37E-55
CORIN Corin, serine peptidase 4.24 5.53E-30
GABRB3 Gamma-aminobutyric acid (GABA) A receptor, beta 3 4.17 1.13E-41
PPP2R2C Protein phosphatase 2, regulatory subunit B, gamma 3.88 1.24E-12
HTR2B 5-Hydroxytryptamine (serotonin) receptor 2B, G protein-coupled 2.94 3.41E-14
DKK2 Dickkopf WNT signaling pathway inhibitor 2 2.77 1.23E-294
SGK1 Serum/glucocorticoid regulated kinase 1 2.73 1.47E-68
SLC18A3 Solute carrier family 18 (vesicular acetylcholine) 3 2.54 6.83E-12
GAD1 Glutamate decarboxylase 1 (brain, 67kDa) 2.44 4.81E-34
GRM8 Glutamate receptor, metabotropic 8 2.35 3.52E-05
CHRM2 Cholinergic receptor, muscarinic 2 2.3 1.15E-11
PLK2 Polo-like kinase 2 2.18 4.14E-79
MAOA Monoamine oxidase A 0.43 2.98E-08
Up regulated
DDC Dopa decarboxylase (aromatic L-amino acid decarboxylase) 1.94 3.16E-287
IGF2 Insulin-like growth factor 2 (somatomedin A) 1.93 1.04E-71
MIR143HG MIR143 host gene (non-protein coding) 1.89 1.95E-03
DBH-AS1 DBH antisense RNA 1 1.77 1.01E-53
SLC18A1 Solute carrier family 18 (vesicular monoamine) 1 1.66 1.75E-229
HTR1E 5-Hydroxytryptamine (serotonin) receptor 1E, G protein-coupled 1.54 5.07E-03
DBH Dopamine beta-hydroxylase (dopamine beta-monooxygenase) 1.35 6.73E-201
SLC6A2 Solute carrier family 6 (neurotransmitter transporter, noradrenalin) 2 0.64 6.07E-49
SLC1A1 Solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter) 1 0.61 1.78E-05
DRD2 Dopamine receptor D2 0.45 7.31E-04
Figure 5. VMAT1, DBH and ASK1 mRNA in oxidized and DJ-1 KD cells. qPCR was performed on SH-SY5Y cells, KD1, WT and DD cells and relative expression calculated.
Data were normalized to b-actin mRNA levels. (A) mRNA levels in DD cells are expressed as % WT levels (n¼4–5). (B) KD1 mRNA levels are expressed as % SH-SY5Y cells
(n¼4–5). (C) SH-SY5Y cells treated with oxidative stress (1 mM BSO for 24 h and 1 mM H2O2 for 30 min; OX) and expressed as % of untreated SH-SY5Y (n¼ 3–5). (D)
mRNA levels in KD1 cells treated with oxidative stress and expressed as % untreated KD1 cells (n¼3–5). Statistical significance calculated using Students T-test versus
respective control. *P<0.05 vs. SH/WT; **P<0.01 vs. WT; ***P<0.001 vs. SH; n.s., non-significant.
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levels, since we were unable to detect formation of HMW
complexes when expressing the intrinsically unstable variant
DJ-1 L166P.
In human brain the levels of HMW DJ-1 complexes were un-
affected in the substantia nigra and amygdala of PD brain, while
it was increased in putamen. To our knowledge, no other
studies have reported DJ-1 complexes in sporadic PD brains.
Further work is required to investigate the role of oxidised DJ-1
in HMW complexes in brain, but also the relevance of the di-
meric form.
Figure 6. Knock down of DJ-1 affects the dopaminergic and noradrenergic system. (A) Overview of catecholamine synthesis pathways. Abbreviations: tyrosine hydroxy-
lase (TH), dopa decarboxylase (DDC), dopamine beta hydroxylase (DBH), phenylethanolamine-N-methyltransferase (PNMT). (B,C) Results of catecholamine ELISA to
measure intracellular levels of dopamine (DA) and noradrenaline (NOR). Catecholamine levels were calculated as pg/mg protein. Results are expressed as percent of
SH-SY5Y cells (n¼ 3). Statistical significance was determined by one-way ANOVA with post hoc Tukey HSD test. *P<0.05 vs. SH; **P<0.01 vs. SH; n.s., non-significant.
Figure 7. Treatment of cells with oxidative stress increased DA and NOR levels. (A,B) Catecholamine ELISAs to measure intracellular levels of noradrenaline (NOR) and
dopamine (DA) in WT and DD cells following treatment with oxidative stress (OX; 1 mM BSO for 24 h and 1 mM H2O2 for 30 min). Catecholamine levels were calculated
as pg/mg protein (n¼3). Statistical significance determined by Students T-test compared to respective control cell line. *P<0.05; **P<0.01; n.s., non-significant.
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Treatment induced oxidative stress or the expression of oxi-
dation mimicking DJ-1 C106 DD and western blotting suggested
oxidation dependent re-organisation of DJ-1 HMW complexes.
Proteomic analysis of HMW complexes revealed the presence of
proteins associated with RNA metabolism, which changed with
the oxidation status of DJ-1. In line with this observation, DJ-1
has been shown to directly bind to mRNA species (17,41), and to
be the regulatory subunit of a 400 kDa RNA binding complex
(29), while SILAC proteomic analysis predicted that 11% of DJ-1
interactors are RNA binding proteins such as members of the
hnRNP protein family (30), which we also found to immunopre-
cipitate with DJ-1. PABP1 was also found to be decreased in cyto-
solic C106DD DJ-1 complexes. This RNA-binding protein has
been shown to relocate from the cytoplasm to the nucleus fol-
lowing treatment with hydrogen peroxide (42). Taken together,
our data further support an oxidation dependent regulatory
function of DJ-1.
Oxidation of DJ-1 at C106 perhaps in combination with addi-
tional redox-sensitive residues (cysteines C46, C53 and methio-
nine residues) has been proposed to act as a regulatory switch
for DJ-1 (8). So far four different oxidation levels for C106 have
been reported, Cys-SH, Cys-SOH, Cys-SO2H, Cys-SO3H (23).
Oxidation of C106 has been shown to be required for protection
against mitochondrial dysfunction (7), oxidative stress and apo-
ptosis via ASK1 (12). However, reports have suggested that the
degree of oxidation may affect DJ-1 function. While mild oxida-
tive stress allows DJ-1 to interact with ASK1 and exert protective
actions, excessive oxidative stress attenuates this interaction
and induces apoptosis (43). Furthermore, the level of -SO2H and
-SO3H oxidation of Cys106 can perturb DJ-1 transcriptional func-
tion, with C106DD perhaps mimicking –SO2H oxidation (18,32).
This might explain the differences in complex size, RNA tran-
scriptome and catecholamine changes between oxidised endog-
enous or WT-DJ-1 complexes and complexes containing the
oxidation mimic C106DD that we observed. The different com-
plexes observed in human brain could reflect the different oxi-
dation states of DJ-1 within these complexes or they could
represent cell type specific forms.
The loss of DJ-1 complexes in KD1 cells might result in the
uncontrolled activity of RNA associated proteins normally part
of these complexes. Subsequent alterations in the transcrip-
tome could therefore trigger changes in the amount or activity
of catecholamine synthesising enzymes such as DBH and
thereby cause impaired regulation of catecholamine synthesis,
storage and/or release.
DJ-1 and catecholamines
Our studies have indicated that oxidation or loss of DJ-1 com-
plexes affected the catecholaminergic system at the transcrip-
tomic level (VMAT1, ASK1, DDC and DBH) and by increasing
intracellular levels of DA and NOR. The increased DA and NOR
levels in DJ-1 KD cells were rescued by re-introduction of either
WT or C106DD DJ-1 further demonstrating the importance of
DJ-1 complexes in catecholaminergic homeostasis. Oxidation of
endogenous DJ-1 or WT-DJ-1 could also increase DA and NOR
levels suggesting that oxidation may fine-tune complex forma-
tion. However, since DD acted the same as WT DJ-1, this sug-
gests that this oxidation mimic may act differently to
complexes following induced oxidative stress, further sup-
ported by the differences observed in complex migration by BN-
PAGE.
It should be noted that steady-state levels of DA, NOR and
AD were measured by ELISA. Therefore, any changes in values
may not only reflect changes in synthesis, but also the seques-
tration, release or turnover of these neurotransmitters: any of
which could be affected by the presence or absence of DJ-1, or
its oxidation status.
In accordance with our findings, changes at the transcrip-
tome or protein level of the catecholamine system have been re-
ported in relation with DJ-1 deficiency. Upon DJ-1 KO, DA
transporter localisation to synaptic membranes increased,
while protein levels were unaffected (44,45). Also, neurotrans-
mitter receptor densities and levels have been reported to be af-
fected by loss-of-DJ-1 (21,44). Altered DBH mRNA levels as well
as total amounts of DBH protein have been observed in PD pa-
tients (46,47), although this is more likely to be reflective of cate-
cholaminergic neuronal loss in substantia nigra and locus
coeruleus, rather than changes in metabolism. Increased DBH
activity has been reported in the medulla oblongata of PD pa-
tients (5). Conversely, polymorphisms decreasing DBH enzyme
activity have been reported to be protective against PD (48,49).
In conclusion, our data suggest that DJ-1 function is required
for catecholamine homeostasis. Fine-tuning of the underlying
mechanism most likely occurs in an oxidation dependent man-
ner, and seems to be mediated via DJ-1 HMW complexes which
regulate the availability of RNA associated proteins. Upon KD of
DJ-1 this regulatory mechanism is lost in neuroblastoma cells,
suggesting that the lack of DJ-1 complexes may contribute to
the increased susceptibility of DA and NOR neurons to neurode-
generation in PARK7-related PD. Since we observed decreased
levels of oxidized DJ-1 in sporadic PD brains, this may affect cat-
echolamine homeostasis in sporadic forms of PD.
Materials and Methods
Human post-mortem brain material
Substantia nigra (n¼ 8) and amygdala (n¼ 5) from control and
PD brains were obtained from the Navarra Brain Bank
(Pamplona, Spain). Frontal cortex was from the Netherlands
Brain Bank. All PD cases met the UK Brain Bank Clinical Criteria
for Parkinson’s disease. None of the cases presented dementia.
All samples were used with the consent of the local ethics com-
mittee. Control and PD samples were age matched (control sub-
stantia nigra, mean age 68.56 4.8 years; post mortem delay,
19.665.2 h; PD substantia nigra, mean age 79.862.9 years; post
mortem delay, 19.263.8 h; control amygdala, mean age
70.263.1 years; post-mortem delay, 4.86 1.0 h; PD amygdala,
mean age 76.261.6 years; post mortem delay, 5.461.3 h).
Samples were assessed to have Braak staging 3–6. The cortex
samples were from 10 agematched controls (n¼ 10, mean age
78.462.6 years, post mortem delay 6.76 0.5 h) and PD patients
(n¼ 10, mean age 71.96 2.0 years, post mortem delay 6.460.5 h).
Cultured cell lines
The human neuroblastoma SH-SY5Y cell line was obtained
from the European Collection of Cell Cultures. SH-SY5Y cell
lines were cultured in DMEM/F-12 Nutrient Mix (1:1) with
GlutaMAXTM-I (Invitrogen) supplemented with 10% (v/v) foetal
calf serum (BioSera), penicillin (50 U/ml final), streptomycin
(50 ng/ml), sodium pyruvate (1 mM) and non-essential amino
acids. To generate DJ-1 KD cells, SH-SY5Y cells were transfected
with pGIPZ lentiviral shRNA plasmid (clone ID: V2LHS_207558;
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Thermo Scientific) encoding siRNA against the 3’UTR of DJ-1
(Target sequence: CCTACAAATTGTGTCTATA). Two DJ-1KD
lines (KD1 and KD2) and a scrambled control cell line (SC1) were
used in this study.
For some experiments KD1 cells were transiently transfected
with the respective DNA constructs (WT DJ-1, oxidation defi-
cient mutant DJ-1 C106A or oxidation mimicking artificial muta-
tion DJ-1 C106DD in mammalian expression vector pCDNA4;
DJ-1 WT or DJ-1 L166P in mammalian expression vector
pCDNA3.1) using xtreme GENE HP DNA transfection reagent
(Sigma) as previously described (50). Briefly, 2  105 cells/ml
were seeded in complete culture medium. Cells were trans-
fected with a mix of 2 mg plasmid DNA and 2 ml of transfection
reagent. Cells were analysed 72 h after transfection. Stable cell
lines expressing DJ-1 WT or DJ-1 C106DD in KD1 cells were gen-
erated using Superfect TR (Qiagen). Briefly, cells were seeded
onto an 8 cm culture dish. When the cells reached 50% conflu-
ency they were transfected with a mix of 4 mg plasmid DNA and
4 ml of transfection reagent. Selection with respective antibiotic
phleomycin (zeocin) was started 48 h later and selection contin-
ued for 6–8 weeks. Colonies were harvested and cultured indi-
vidually and positive clones were analysed for the presence of
DJ-1 by western blot.
Stress treatment to induce intracellular oxidative stress
To induce intracellular oxidative stress, cells were pre-treated
with 1 mM buthionine sulfoximine (BSO) for 24 h to reduce glu-
tathione levels (51) and subsequently treated with 1 mM H2O2
for 1 h. No significant cell death was observed. For stress treat-
ments prior to qPCR analysis or ELISA, cells were left for an ad-
ditional hour in fresh media to recover.
Homogenisation of post-mortem brain tissue
For SDS PAGE analysis brain tissue was homogenised (10 mg/
100 ll buffer) in 10 mM Tris, pH7.4, 150 mM NaCl, 0.1% (w/v) SDS,
DNase (50 Units; Promega), 1X DNase buffer and protease inhibi-
tors using a plastic homogeniser in 1.5 mL reaction tubes.
Samples were then homogenised at 1000 rpm until homoge-
nous. Samples were then incubated at 37 C for 1 h to digest
DNA.
Polyacrylamide gel electrophoresis
Blue native polyacrylamide gel electrophoresis (BN PAGE) was
performed as described by Scha¨gger et al. (52). Protein extraction
was performed by sonication of brain/SH-SY5Y cell pellets in
sucrose buffer (250 mM Sucrose, 10 mM HEPES, 1.5 mM MgCl2,
10 mM KCl, pH 7.0) applying pulses of 5 s (cells: 1 pulse at 50%
intensity and 3 pulses at 30% intensity; brain: 2 pulses at 50%
intensity and 3 pulses at 30% intensity) with breaks of 30 s on
ice. Protein (25–80 mg) was separated on 7.5% fixed percentage
gels or gradient gels (8–16%) when resolving monomeric, di-
meric and complex bound DJ-1. In order to denature HMW com-
plexes and to facilitate protein transfer to Hybond P membrane
(GE Healthcare), gels were incubated in solubilisation buffer (2%
(w/v) SDS, 66 mM Sodium hydrogen carbonate, 2% (v/v) b-mer-
captoethanol, 6 M urea) for 20 min on a shaker and subsequently
washed in transfer buffer (20% (v/v) methanol, 25 mM Tris pH
8.8, 0.2 M glycine) for 10 min prior to transfer.
SDS PAGE was performed using NuPAGEVR 12% or NuPAGEVR
4–12% gels (Invitrogen). SH-SY5Y cells were harvested with
trypsin and lysed on ice in 0.1–0.2% (v/v) SDS in Tris-HCl, pH 7.4
supplemented with protease inhibitor cocktail (Pierce) and
Benzonase (Merck Millipore). Protein samples (50mg) were
mixed with SDS sample loading buffer and 1X reducing agent
(both Invitrogen) and heated to 70 C for 5 min. An aliquot of
protein samples prepared for BN-PAGE above were denatured
and heated in a similar fashion to check for b-actin levels as a
further loading control.
For two-dimensional BN/SDS PAGE, samples were separated
by BN PAGE as above except 50 mg protein was used. Gel lanes of
interest were cut out, incubated in solubilisation buffer (2%
(w/v) SDS, 66 mM Sodium hydrogen carbonate, 2% (v/v) b-mer-
captoethanol) for 10 min at room temperature (RT) on a shaker
and subsequently washed in equilibration buffer (50 mM Tris,
1% (w/v) SDS) for 2  10 min at RT on a horizontal shaker. Pre-
treated gel strips were placed between Mini-ProteanVR 0.75 mm
glass plates (BioRad) and cast in 4% polyacrylamide-SDS-urea
stacking gel. Protein was then separated in the second dimen-
sion using a 12.5% polyacrylamide-SDS-urea resolving gel.
Western blotting analysis
Separated proteins were transferred to Hybond P membrane (GE
Healthcare). BN PAGE membranes were destained with metha-
nol and stained with Ponceau to mark protein ladder (Native
Mark Unstained Protein Standard, Life Technologies) and check
for equal protein loading. Membranes were blocked for 30 min
at room temperature in 10% milk in PBS and subsequently
probed with monoclonal mouse anti-total DJ-1 (3E8, Enzo Life
Sciences; 1:5,000), monoclonal mouse anti-oxidised DJ-1 (clone
M106, kind gift from Yoshiro Saito; 1:1,000), anti-hnRNPA1
(abcam ab50966; 1:1000), anti-GAPDH (abcam ab8245; 1:40,000),
anti-hsc70 (abcam ab51052), anti-PABP1 (abcam ab21060; 1:50)
and anti-b-actin (abcam ab82618; 1:50,000). After washing
with PBS/0.4% (v/v) Tween20 (PBS/T), blots were incubated with
respective horse radish peroxidase-coupled secondary antibod-
ies (Dako). Blots were developed with either in-house chemi-
luminescence solution or enhanced chemiluminescence kit
(Pierce). Densitometry of bands was quantified using imageJ
(NIH).
Co-immunoprecipitation of HMWDJ-1 complexes
Co-immunoprecipitation was performed using the Novex
DynabeadsVR system (Invitrogen). First, polyclonal goat anti DJ-1
antibody (ab4150; abcam) was covalently linked to DynabeadsVR
M-270 Epoxy beads using the DynabeadsVR Antibody Coupling
Kit (Invitrogen) following the manufacturer’s instructions.
Typically 10 mg of antibody was used per 1 mg of DynabeadsVR M-
270 Epoxy. For the co-immunoprecipitation reaction, six conflu-
ent 10 cm tissue culture dishes of SH-SY5Y cells were harvested
by trypsination and washed in PBS. Cells were lysed in 50 mM
Tris, 0.27 M sucrose, 1 M sodium orthovanadate, 1 mM EDTA,
1 mM EGTA, 10 mM b-glycerophosphate, 5 mM pyrophosphate,
50 mM sodium fluoride, 1% NP40, 150 mM sodium chloride; pH
7.5 and cell lysates were concentrated to a volume of 500 ml us-
ing AmiconVR Ultra Centrifugal Filters UltracelVR -100 K (Milipore)
in order to remove proteins less than 100 kDa, including mono-
meric and dimeric DJ-1. Lysate was then incubated with the
antibody-bound beads for 1 h at 4 C. The beads were then
washed twice with PBS and stored in PBS at 4 C until subse-
quent mass spectrometric analysis was performed.
4038 | Human Molecular Genetics, 2017, Vol. 26, No. 20
Label-free quantitative liquid chromatography tandem
mass spectrometry (LC-MS/MS)
LC-MS/MS analysis was performed at the Biological Mass
Spectrometry Facility at the Institute of Child Health, University
College London, UK. Briefly, samples were reduced, alkylated
and subjected to trypsination over night at 37 C. After diges-
tion, 10 ll of neat supernatant (or 9 ll of supernatant and 1 ll of
yeast enolase) was pipetted into a sample vial and loaded on to
an autosampler for automated liquid chromatography (LC) tan-
dem mass spectrometry (MS/MS) analysis. All LC–MS/MS experi-
ments were performed using the nanoAcquity UPLC and QTOF
Premier mass spectrometer (Waters Corporation, Manchester,
UK). After the run, data were processed using ProteinLynx
Global server 2.5 (PLGS) software. All samples were analysed in
quadruplicates. Quantification data were obtained at least in a
triplicate; ID data in a quadruplicate. Quantification data were
obtained as recently described by Manwaring et al. (37).
Quantitative real-time PCR
RNA was extracted from cells with RNeasy mini kit (Qiagen) and
500 ng RNA converted to cDNA with reverse transcriptase
(Primerdesign). DJ-1 mRNA levels were measured with Power
SYBRgreen and a STEP One PCR machine (Applied Biosystems).
Data were normalised against b-actin by the DCT method (DJ-1
primer sequences: forward, 5’-TGGCTGGAAAAGACCCAGTA-3,
reverse, 5’-CCTTCACAGCAGCAGACTCA-3’; b-actin, forward,
5’-TCTACAATGAGCTGCGTGTG-3’, reverse, 5’-GGTGAGGATCTT
CATGAG GT-3’VMAT1 forward, 5’-GGTGGATTCTTCTATGATG
CCC-3’, reverse, 5’-GTGGATGGACCTATAGCAAAG-3’, DBH for-
ward, 5’-GGCCGGGAGTGGGAGATCGT-3’, reverse, 5’-TGTGGCC




RNA and small RNA sequencing experiments were performed
as previously described (53,54). In brief, RNA-seq and small
RNA-seq libraries were prepared using the TruSeqVR RNA Sample
Preparation v2 kit and the TruSeqVR Small RNA Preparation kit
from Illumina according to the manufacturer’s instructions.
The library quality was assessed using an Agilent 2100
Bioanalyzer. Sample concentrations were measured using a
Qubit dsDNA HS Assay Kit and adjusted to 2 nM before sequenc-
ing (50 bp single end) on a HiSeq 2000 instrument (Illumina) us-
ing TruSeq SR Cluster Kit v3-cBot-HS and TruSeq SBS Kit v3-HS
according to the manufacturer’s instructions.
RNA-sequencing data were analyzed using in-house work-
flows and resulted in 17–32 million reads per sample
(Supplementary Material, Table S3). Quality assessment was
based on the raw reads using the FASTQC quality control tool
(v0.10.1). The sequence reads (single-end 50 bp) were aligned to
the human reference genome (hg19) with STAR aligner
(2.3.0e_r291). Read counts for all genes and all exons (Ensembl
annotation v72) were obtained using FeaturesCount (version
1.4.6). Differential expression analysis was carried out using
gene read counts with DESeq2 package (v1.4.5) (55). Genes with
less than 10 reads (baseMean) were filtered out. Genes with a p
value  0.05 and log2 fold change> 0.5 were considered to be
differentially expressed. Small RNA-sequencing data were ana-
lyzed with the Oasis sRNA detection and differential expression
modules using standard parameters and resulted in 13.78 x 106
and 12.45 x 106 reads per sample for WT and DD samples, re-
spectively (56).
To identify enriched GO categories, the web-service
WebGestalt was used. GO category enrichment was assessed by
calculating the fold-change between observed and expected
number of genes of a given GO category, where terms were
scored enriched if they had an adjusted P value< 0.05. In addi-
tion, we used QIAGEN’s IngenuityVR Pathway Analysis (IPAVR ;
www.qiagen.com/ingenuity) to obtain RNA-miRNA correlation
and pathway information.
Catecholamine ELISA to measure intracellular levels of
DA, noradrenaline and adrenaline
To measure catecholamine levels in the different SH-SY5Y cell
lines TriCat ELISA from IBL International (Germany) was used
according to the manufacturer’s instructions. Briefly, around
100  106 cells were harvested in Versene (Invitrogen) supple-
mented with 0.125% (v/v) Trypsin (Invitrogen), washed in PBS,
and pelleted at 400  g for 10 min. The pellet was subsequently
resuspended in 100 ml ddH2O, sonicated with two pulses at 50%
intensity for 5 s and cooled on ice for 30 s in between. The lysate
was then made up to 500 ml with ddH2O and used to extract cat-
echolamines in extraction buffer as supplied by the manufac-
turer. Values were normalised against protein concentration of
the samples.
Supplementary Material
Supplementary Material is available at HMG online.
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